Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. BioHarvest Sciences's Total Liabilities for the quarter that ended in Mar. 2026 was $22.54 Mil. BioHarvest Sciences's Total Assets for the quarter that ended in Mar. 2026 was $45.56 Mil.
Therefore, BioHarvest Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.50.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
BioHarvest Sciences Liabilities-to-Assets Related Terms
BioHarvest Sciences Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for BioHarvest Sciences's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BHST vs BFNH, LSF, HAIN: Liabilities-to-Assets Comparison
For the Packaged Foods subindustry, BioHarvest Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences Liabilities-to-Assets vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
BioHarvest Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioHarvest Sciences (BHST) has a Liabilities-to-Assets of 0.50 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on BioHarvest Sciences and its competitors.
Is BioHarvest Sciences' Liabilities-to-Assets too high?
BioHarvest Sciences' current Liabilities-to-Assets is 0.50. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Liabilities-to-Assets compare to BFNH and LSF?
BioHarvest Sciences' Liabilities-to-Assets of 0.50 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Consumer Packaged Goods company?
A good Liabilities-to-Assets depends on the Consumer Packaged Goods industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on BioHarvest Sciences and its competitors. BioHarvest Sciences's current Liabilities-to-Assets is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.61, compared to a current price of $2.26 — trading 73.8% below its estimated fair value. The current Liabilities-to-Assets is 0.50. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current Liabilities-to-Assets is 0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (BHST) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of $2.26 is trading 73.8% below its estimated GF Value™ of $8.61.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for BHST:
Liabilities-to-Assets: 0.50
GF Value™: $8.61 vs. price of $2.26 (73.8% below fair value)
No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
63GF Score
Get the complete analysis for BHST
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHST has been successfully added to your 
